| IgAN-I | IgAN-II | IgAVN-I | IgAVN-II | Controls |
---|---|---|---|---|---|
Number of patients and controls | 6 | 6 | 6 | 6 | 5 |
Median age (years) (range) | 42 (16‒71) | 67 (22‒76) | 71 (36‒78) | 60 (34‒74) | 53 (45‒77) |
Male:female | 3:3 | 2:4 | 2:4 | 2:4 | 1:4 |
Chance proteinuria and/or hematuria, n | 6 | 0 | Â | Â | Â |
Urinary abnormalities after the onset of purpura, n | Â | Â | 6 | 6 | Â |
Progressive renal dysfunction, n | 1 | 3 | 0 | 1 | Â |
Edema, n | 0 | 5 | 0 | 2 | Â |
Hypertension, n | 2 | 4 | 1 | 4 | Â |
RAS-I/CCB/SARA/AB/BB/DU, n | 2/1/0/0/0/0 | 1/3/1/1/0/0 | 1/1/0/0/0/0 | 3/2/0/1/1/2 | Â |
Purpura, n | Â | Â | 6 | 6 | Â |
Arthralgia, n | Â | Â | 0 | 1 | Â |
Abdominal pain, n | Â | Â | 0 | 1 | Â |
Median proteinuria (g/day or g/gCr) at biopsy (range) | 0.4 (0.1–2.8) | 5.9 (4.1‒10.0) | 3.6 (0.2‒7.9) | 2.0 (0.5‒6.4) | 0.7 (0.1‒0.9) |
Median serum albumin (g/dL) (range) | 4.0 (3.5‒4.7) | 2.5 (2.2‒2.8) | 3.5 (1.8‒4.3) | 3.6 (2.5‒3.9) | 4.3 (3.5‒4.5) |
Nephrotic syndrome, n | 0 | 6 | 1 | 2 | Â |
Median serum Cr (mg/dL) (range) | 0.89 (0.50‒1.85) | 1.13 (0.62‒2.07) | 0.79 (0.48‒1.18) | 0.76 (0.59‒2.10) | 0.67 (0.60‒0.90) |
Median eGFR (mL/min/1.73 m2) (range) | 77.8 (32.6‒109.3) | 55.6 (22.4‒73.6) | 66.0 (34.5‒98.4) | 59.2 (25.1‒92.8) | 72.1 (66.9‒81.6) |
Median serum IgA (mg/dL) (range) | 439 (213‒921) | 322 (189‒528) | 305 (254‒410) | 330 (214‒382) |  |